Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000186726 | SCV000240293 | uncertain significance | not provided | 2023-11-16 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000702625 | SCV000831485 | likely benign | Pyridoxine-dependent epilepsy | 2025-01-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002517836 | SCV003706622 | uncertain significance | Inborn genetic diseases | 2022-11-30 | criteria provided, single submitter | clinical testing | The c.553G>A (p.V185I) alteration is located in exon 6 (coding exon 6) of the ALDH7A1 gene. This alteration results from a G to A substitution at nucleotide position 553, causing the valine (V) at amino acid position 185 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004755798 | SCV005362468 | uncertain significance | ALDH7A1-related disorder | 2024-06-18 | no assertion criteria provided | clinical testing | The ALDH7A1 c.553G>A variant is predicted to result in the amino acid substitution p.Val185Ile. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.023% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |